Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multi-center, Open-label, Cross-over Study Comparing Critical Errors, Overall Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA Dry Powder Inhaler Versus the BREEZHALER Dry Powder Inhaler, in Adult Participants With Mild to Moderate Asthma

NCT04813354 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT04813354
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04813354 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multi-center, Open-label, Cross-over Study Comparing Critical Errors, Overall Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA Dry Powder Inhaler Versus the BREEZHALER Dry Powder Inhaler, in Adult Participants With Mild to Moderate Asthma
Lead sponsor
GlaxoSmithKline
Phase
Phase 4
Overall status
Completed
Start date
April 14, 2021
Completion date
July 8, 2021
Enrollment
114 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

asthma